Arrowhead Pharmaceuticals, Inc.
Every calculator, already run for ARWR
Open the full toolkit →You have the numbers on ARWR. Get the argument.
A written report on which of these readings actually decide the outcome for Arrowhead Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
12 analysts covering ARWRAnalyst Price Target Disagreement for Arrowhead Pharmaceuticals, Inc.
Wall Street's bull case implies +46% from the current price; the bear case implies +16%. A 30% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for ARWR
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clin…
ARWR — frequently asked
Is ARWR a buy right now?
Wall Street's consensus rating on Arrowhead Pharmaceuticals, Inc. is Strong Buy across 12 analysts, with a mean price target of $110.18 (+28% vs. the current $86.34). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is ARWR's next earnings date?
Arrowhead Pharmaceuticals, Inc. is next scheduled to report earnings around Nov 24, 2026. A full ARWR research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Arrowhead Pharmaceuticals, Inc.?
Analysts covering Arrowhead Pharmaceuticals, Inc. (ARWR) range from a bear-case target of $100.00 to a bull-case high of $126.00, with a mean consensus target of $110.18 across 11 analysts. The spread of $26.00 (30% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Arrowhead Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Arrowhead Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ARWR research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Arrowhead Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.